Some natural anti-αGal antibodies can shield Gram-negative bacteria from complement-mediated killing. RA0127 is a soluble glycopolymer designed to bind these antibodies inside the body so that the resulting complexes can be cleared through normal physiological pathways. By removing an inhibitory immune signal rather than suppressing immunity, DITRAP seeks to restore the body’s ability to eliminate harmful bacteria without adding antimicrobial selective pressure.
DITRAP will develop and validate models that use information from the first 24 hours of ICU admission to predict a stay of at least seven days, a strong marker of infection risk. Literature-informed Bayesian modelling and established machine-learning methods will support early model development, followed by validation on independent and multicentre datasets
The TEAGAR study is a randomised, double-blind, placebo-controlled Phase 2 trial planned in 296 adults across at least 15 ICUs in France, Italy, Portugal and Spain. It will evaluate sustained reduction of anti-αGal antibodies and examine ICU-acquired infections, antibiotic use, inflammation, safety, mortality and length of stay. Participants will be identified early through AI-supported risk assessment, and independent safety oversight will be provided by a Data Safety Monitoring Board.
